Professional Documents
Culture Documents
review article
Current Concepts
Nanomedicine
Betty Y.S. Kim, M.D., Ph.D., James T. Rutka, M.D., Ph.D.,
and Warren C.W. Chan, Ph.D.
M
From the Institute of Biomaterials and any diseases originate from alterations in biologic processes
Biomedical Engineering (B.Y.S.K., W.C.W.C.), at the molecular or nanoscale level. Mutated genes, misfolded proteins,
Terrence Donnelly Centre for Cellular and
Biomolecular Research (B.Y.S.K., W.C.W.C.), and infections caused by viruses or bacteria can lead to cell malfunction
the Department of Materials Science and or miscommunication, sometimes leading to life-threatening diseases. These mol-
Engineering (W.C.W.C.), and the Depart- ecules and infectious agents are nanometers in size and may be located in biologic
ment of Chemical Engineering (W.C.W.C.),
University of Toronto (B.Y.S.K., J.T.R., systems that are protected by nanometer-size barriers, such as nuclear pores 9 nm
W.C.W.C.); and the Division of Neurosur- in diameter. Their chemical properties, size, and shape appear to dictate the trans-
gery (B.Y.S.K., J.T.R.) and the Arthur and port of molecules to specific biologic compartments and the interactions between
Sonia Labatt Brain Tumour Research
Centre (J.T.R.), Hospital for Sick Children molecules.
(B.Y.S.K., J.T.R.) both in Toronto. Ad- Nanotechnology is defined as the intentional design, characterization, produc-
dress reprint requests to Dr. Chan at the tion, and applications of materials, structures, devices, and systems by controlling
Institute of Biomaterials and Biomedical
Engineering, Donnelly Centre for Cellular their size and shape in the nanoscale range (1 to 100 nm).1 Because nanomaterials
and Biomolecular Research, 164 College are similar in scale to biologic molecules and systems yet can be engineered to have
St., 407, University of Toronto, Toronto, ON various functions, nanotechnology is potentially useful for medical applications.
M5S 3G9, Canada, or at warren.chan@
utoronto.ca. The field of nanomedicine aims to use the properties and physical characteristics of
nanomaterials for the diagnosis and treatment of diseases at the molecular level.
N Engl J Med 2010;363:2434-43. Nanomaterials are now being designed to aid the transport of diagnostic or
Copyright 2010 Massachusetts Medical Society.
therapeutic agents through biologic barriers; to gain access to molecules; to medi-
ate molecular interactions; and to detect molecular changes in a sensitive, high-
throughput manner. In contrast to atoms and macroscopic materials, nanomaterials
have a high ratio of surface area to volume as well as tunable optical, electronic,
magnetic, and biologic properties, and they can be engineered to have different
sizes, shapes, chemical compositions, surface chemical characteristics, and hollow
or solid structures.2,3 These properties are being incorporated into new genera-
tions of drug-delivery vehicles, contrast agents, and diagnostic devices, some of
which are currently undergoing clinical investigation or have been approved by the
Food and Drug Administration (FDA) for use in humans. Examples of the nano-
materials most commonly used in medicine are provided in Figure 1 and Table 1. This
overview describes the properties of nanomaterials, their principal medical appli-
cations, and the future possibilities for this emerging field.
Over the past three decades, physical scientists have developed strategies to repro-
ducibly synthesize nanomaterials and to characterize their unique, size-dependent
properties.2,3 An understanding of these fundamental physical and chemical prop-
erties is necessary for the optimal use of nanomaterials in medical applications.
Nanomaterials generally consist of metal atoms, nonmetal atoms, or a mixture
of metal and nonmetal atoms, commonly referred to as metallic, organic, or semi-
conducting particles, respectively. The surface of nanomaterials is usually coated with
polymers or biorecognition molecules for improved biocompatibility and selective
targeting of biologic molecules. The final size and aging (MRI), since more protons interact in a
structure of nanomaterials depend on the salt and larger field.
surfactant additives, reactant concentrations, re- In cadmium selenide semiconductor nano-
action temperatures, and solvent conditions used structures that are less than 10 nm in diameter
during their synthesis. (known as CdSe quantum dots, or Qdots), the
A common feature of all nanomaterials is their electrons can transition between two energy lev-
large ratio of surface area to volume, which may be els: a ground state, in which the electrons are at
orders of magnitude greater than that of macro- rest, and an excited state, in which they are mo-
scopic materials.4 Cutting a 1-cm cube into 1021 bile (Fig. 2B).6 The difference between the ground
cubes that are each 1 nm on a side will result in and excited energy levels dictates the color and
the same overall volume and mass, but the surface fluorescence emission of these nanostructures.
area will be increased by a factor of 10 million. This energy difference is size-dependent and can
Thus, the advantage of using nanomaterials as car- be observed under ultraviolet light by means of
riers is that their surface can be coated with many the fluorescence emissions of Qdots of different
molecules. sizes. Furthermore, the magnetic and optical sig-
Unique aspects of metal-containing materials nals from these inorganic nanomaterials tend to
with at least one dimension that is smaller than be stronger than their traditional molecular coun-
100 nm are their size, shape, and composition- terparts because a larger number of electrons are
tunable electronic, magnetic, and optical proper- involved. To illustrate this point, the absorption
ties. This relationship is a direct consequence of cross section of Qdots, a measure of the number
the behavior of electrons in the nanomaterial. Elec- of electrons that transition from the ground to
trons have two important characteristics: their the excited state, is at least 10 times that of or-
spin and their ability to move in a quantized fash- ganic fluorescent dye molecules.6
ion between specific energy levels. Electrons are
similar to tiny bar magnets, with a surrounding Na nom ater i a l s for in V i vo
magnetic field that corresponds to the electron A ppl ic at ions
spin in an applied field. Also, after absorbing en-
ergy, electrons can generate light or heat when A handful of nanomaterials are being studied in
they move between different energy levels (Fig. 2). clinical trials or have already been approved by the
In macrostructures, electrons can spin in two FDA for use in humans,3,7,8 and many proof-of-
directions, in opposition or in alignment, and can concept studies of nanomaterials in cell-culture
move among many energy levels. The behavior and small-animal models for medical applications
of electrons in nanostructures is more constrained are under way.6,9,10 Many of these nanomaterials
and depends on the size or shape of the material are designed to target tumors in vivo and are in-
or on the electrons interactions with the surface tended for use either as drug carriers for thera-
coating. The chemical composition of a nanoma- peutic applications or as contrast agents for diag-
terial determines whether one or both electron nostic imaging (Fig. 3). Nanomaterials infused
characteristics (spin and energy transition) are into the bloodstream can accumulate in tumors
affected, as well as the extent of that effect. For owing to the enhanced permeability and reten-
example, all electrons in iron oxide magnetic tion effect when the vasculature of immature tu-
nanoparticles (20 nm in diameter) spin in the mors has pores smaller than 200 nm, permitting
same direction, whereas electrons in iron oxide extravasation of nanoparticles from blood into tu-
macroparticles (>20 nm in diameter) spin in op- mor tissue.11 The infusion of antineoplastic drugs
posite directions (Fig. 2A).5 When these spins are with nanomaterials as carriers results in an in-
aligned in the same direction, the field becomes creased payload of drugs to the tumor, as com-
additive, but when the electrons spin in opposite pared with conventional infusion. With nanoma-
directions, the fields cancel each other out. Since terials, the high ratio of surface area to volume
the overall magnetic-field strength of a material is permits high surface loading of therapeutic agents;
the sum of the magnetic fields of individual in the case of organic nanomaterials, their hollow
electrons, these nanoparticles have a larger, local- or porous core allows encapsulation of hundreds
ized magnetic field as compared with that of of drug molecules within a single carrier particle.
larger particles. This larger magnetic field can When the carrier particle degrades, the drug mole
increase the contrast on magnetic resonance im- cules are released, and the rate of degradation
Nanomaterials in clinical
nm
trials or FDA-approved
108 Baseball
Liposome
107
106
Dendrimer
105 Hair
Gold nanoparticle
103 Bacteria
Gold nanorod
102 Virus
Quantum dot
101 DNA
1 Glucose molecule
Fullerene
COLOR FIGURE
Draft 3 11/12/10
Author Chan (Kim)
n engl j med 363;25 nejm.org december 16, 2010 Fig # 1 2437
Title
The New England Journal of Medicine
ME
Downloaded from nejm.org at UNIVERSITY MASS MEDICAL SCHOOL on October 30, 2012. For personal use only. No other uses without permission.
DE Campion
Copyright 2010 Massachusetts Medical Society. All rights reserved.
Artist Knoper
The n e w e ng l a n d j o u r na l of m e dic i n e
Nanomaterial Trade Name Application Target Adverse Effects Manufacturer Current Status
Metallic
Iron oxide Feridex MRI contrast Liver Back pain, vaso Bayer Schering FDA approved
dilatation
Resovist MRI contrast Liver None Bayer Schering FDA approved
Combidex MRI contrast Lymph nodes None Advanced Magnetics In phase 3 clin-
ical trials
NanoTherm Cancer therapy Various forms Acute urinary MagForce In phase 3 clin-
retention ical trials
Gold Verigene In vitro diag Genetic Not applicable Nanosphere FDA approved
nostics
Aurimmune Cancer therapy Various forms Fever CytImmune Sciences In phase 2 clin-
ical trials
Nanoshells Auroshell Cancer therapy Head and neck Under investigation Nanospectra In phase 1 clin-
Biosciences ical trials
Semiconductor
Quantum dot Qdots, EviTags, Fluorescent con- Tumors, cells, Not applicable Life Technologies, Research
semiconductor trast, in vitro tissues, and eBioscience, use only
nanocrystals diagnostics molecular Nanoco,
sensing CrystalPlex,
structures Cytodiagnostics
Organic
Protein Abraxane Cancer therapy Breast Cytopenia Abraxis Bioscience FDA approved
Liposome Doxil/Caelyx Cancer therapy Various forms Handfoot syndrome, Ortho Biotech FDA approved
stomatitis
Polymer Oncaspar Cancer therapy Acute lymphoblas- Urticaria, rash Rhne-Poulenc Rorer FDA approved
tic leukemia
CALAA-01 Cancer therapy Various forms Mild renal toxicity Calando In phase 2 clin-
ical trials
Dendrimer VivaGel Microbicide Cervicovaginal Abdominal pain, Starpharma In phase 2 clin-
dysuria ical trials
Micelle Genexol-PM Cancer therapy Various forms Peripheral sensory Samyang For phase 4
neuropathy, clinical
neutropenia trials
sia, adenoma, and more specifically, primary lung are used in lateral-flow in vitro diagnostic assays
cancer, in which a decrease in the function of the (LFA) (as described below), such as the urine preg-
reticuloendothelial system affects the amount of nancy test for detecting protein markers (e.g., hu-
nonspecific phagocytic uptake. man chorionic gonadotropin [hCG]).20 The hCG
molecule is introduced into a membrane strip,
which moves through the membrane by capillary
Na nom ater i a l s for in V i t ro
Di agnosis force and initially interacts with anti-hCG anti-
bodycoated gold nanoparticles. On successful
The second key application of nanomaterials is binding, this complex moves through the mem-
as a label for measuring molecules of interest in brane until it recognizes a region that is also
biologic samples. Nanomaterials are used to ei- coated with anti-hCG antibody. The complex be-
ther simplify the readout or amplify the detection comes tethered to the membrane surface as a
threshold of the diagnostic device. Nanoparticles result of the antigenantibody interaction. The
A single domain
Excited state
Ground state
Fluorescence
Cadmium
selenide Qdot
2 nm 4 nm 6 nm
Imaging Drug-carrying
nanoparticle nanoparticle
Tumor cells
Tumor
Figure 3. Nanomaterials Used as Drug Carriers or Contrast Agents for In Vivo Cancer Applications. COLOR FIGURE
Draft 3
Tumors have poor lymphatic drainage, and their vessels are highly porous. This enables nanomaterials 11/15/10
to diffuse
Author Chan (Kim)
and accumulate in the tumor matrix. Nanomaterials that carry chemotherapeutic agents can target and kill tumor
Fig # 3
cells, whereas nanomaterials that are magnetic or fluorescent are used as imaging agentsTitle
for detecting tumors.
ME
DE Campion
accumulation of gold nanoparticles in this re- quences is coated onto a Artist
microarray Knoper
surface. Iso-
AUTHOR PLEASE NOTE:
gion of the membrane now appears red, which is lated and purified genetic materials obtained
Figure has been redrawn from
and type has been
Please check carefully
reset
deeper and richer in color than that of organic patient samples are introduced into the microar-
Issue date 12/16/10
chromophores because the gold nanoparticles ray, followed by incubation with gold-nanoparti-
have a larger cross section of absorption. This cle probes. Gene-specific oligonucleotides link the
allows an easier readout of the signal at the point gold nanoparticles to the surface. Finally, the
of care without the need for a more complex in- sample is washed to remove the unbound parti-
strument. A number of FDA-approved LFAs for cles and is then amplified by reducing the re-
measuring human immunodeficiency virus (HIV), maining gold nanoparticles with the chemical
malaria, and cardiac markers are also available. agents silver nitrate and hydroquinone to produce
Although this technique is simple to use and can a black spot on the microarray. This approach does
be carried out rapidly (in less than 1 hour), it suf- not suffer from the problems often associated
fers from poor detection thresholds (millimolar with conventional fluorescent probes for micro-
to micromolar, depending on the biomarker). array labeling, such as photobleaching (loss of
Gold nanoparticles are also used in high- signal after exposure to light), and can detect mul-
throughput genomic detection devices without the tiple markers with a high sensitivity (95%) and low
need for polymerase-chain-reaction (PCR) ampli- detection threshold (1018 M). A modification of
fication but with a sensitivity similar to that of this approach called the bio-barcode assay is cur-
PCR-based assays (Fig. 4).21 This technology has rently being validated for the detection of pro-
been approved by the FDA for genetic screening teins found in prostate cancer.23
to determine drug sensitivity and to detect ge-
netic mutations. One particular application is in O ther Na nom ater i a l -b a sed
screening for single-nucleotide polymorphisms of Cl inic a l A ppl ic at ions
the factor V and factor II genes and the 5,10-
methylenetetrahydrofolate reductase gene, in which Nanomaterials are being put to other clinical uses.
the mutations are related to thrombophilia and For example, gold nanoshells, which comprise a
hyperhomocysteinemia.22 A library of genetic se- silica core coated with a thin layer of gold, are
Purified patient
DNA samples
Capture
molecule
Binding
occurs when
sequences
match
Gold
nanoparticles
(GNPs) with
complementary patient
DNA probes are incubated
over the array
The nanosignal is
amplified by reducing the
GNPs with silver nitrate
Figure 4. Nanomaterials Used as Labels to Amplify Detection Signals in Diagnostic Devices. COLOR FIGURE
Nanomaterials such as gold nanoparticles can be coated with biorecognition molecules to target either a patients DNA Draft 5or a protein 11/30/10
sam-
Author Chan
ple. Here, gold nanoparticles are coated with a complementary oligonucleotide (single-stranded DNA) that recognizes (Kim) gene se-
the variant
Fig # 4
quence captured on a surface. Once nanoparticles are bound to the surface, the signal is amplified by means of a silver nitrate reduction
Title
reaction. This technique has been reported to have sensitivity equivalent to that of the polymerase-chain-reaction assay for genetic analysis.
ME
DE Campion
Artist Knoper
being used for the treatment of recurrent head ing and subsequent cell death. Rod-shaped gold AUTHOR PLEASE NOTE:
and neck tumors. In this application, the nano nanoparticles25 and carbon nanotubes canFigure also
has been redrawn and type has been reset
Please check carefully
shells are injected into the tumor and then illu- produce heat on optical excitation, but to date
Issuetheir
date 12/16/10
minated with 700-nm to 800-nm light.24 Electrons use has been limited to mouse models.
excited by these wavelengths interact with the sur- Nanomaterials are also being evaluated in
rounding water molecules, causing localized heat- clinical trials as agents for inhibiting the spread
of sexually transmitted diseases (NCT00370357, trast, numerous studies have shown that certain
NCT00442910, and NCT00740584). These nano- nanomaterials do not elicit toxic responses in ani-
materials are engineered to disrupt the biolog mals, as determined by histopathological studies
ic interactions between the pathogen and the and analyses of hepatic and renal markers.32,33
host.7,26 Dendrimers, which are nanostructures The issue of nanomaterial toxicity remains con-
that look like tree branches (Fig. 1), have been troversial and requires more study.
shown to prevent the transmission of HIV in Nanomaterials are frequently used in basic re-
macaque models. The mechanism of inhibition search as probes for studying the molecular basis
depends on the dendrimers surface chemical fea- of diseases or in proof-of-concept studies per-
tures and size. Dendrimers with benzene dicar- formed to demonstrate their medical usefulness.
boxylate on the surface inhibit HIV from entering For example, fluorescence microscopy revealed the
the cell by binding to its viral capsid; conversely, binding and transport of Qdots coated with epi-
dendrimers with naphthalene disulfonate on the dermal growth factor to ErbB/Her receptors over-
surface enter the cells and inhibit reverse-tran- expressed in breast and ovarian cancer, thereby
scriptase and integrase activity. These differen- allowing researchers to identify the specific re-
tial cellular-uptake mechanisms have not been ceptor subtype responsible for this molecular in-
fully elucidated and are under investigation.27 teraction.34 Nanomaterials are being explored
The two enzymes mentioned are involved in for many applications, including cell and tissue
translating the RNA from HIV into DNA and screening35 and in vivo targeting of tumors with
integrating it into the host DNA. It has been the use of nanoparticles coated with antibodies,
proposed that the dendrimer size mimics the peptides, or oligonucleotides folded into complex
ligand, whereas its multivalency strengthens the structures called aptamers.36,37 In addition, nano-
interaction with the biologic target. In both cases, materials are being used as platforms for design-
the therapeutic benefit persists because the virus ing multifunctional agents with diagnostic and
cannot function normally and cannot be trans- therapeutic capabilities (silicon nanostructures
mitted from one macaque to another. that contain the DNA-intercalating drug doxoru-
bicin with luminescence properties for imag-
ing)38,39; and as antioxidants (fullerenes, or
Cur r en t Ch a l l enge s
a nd F u t ur e Ou tl o ok buckyballs, which contain about 30 double
bonds that react with free radicals in tissues).40
There is growing speculation about possible nano- To translate these applications into clinical use,
material toxicity on the basis of in vitro cell-cul- researchers must optimize the nanomaterials, be-
ture studies and in vivo animal studies. For ex- ginning with small-animal models and scaling
ample, the metabolism of CdSe Qdots leads to up to nonhuman primate models a process
cadmium toxicity, with adverse effects on the func- that will take some time. These studies should
tion, viability, and morphologic features of pri- provide a solid foundation for the long-term ad-
mary (freshly isolated) rat hepatocytes.28 Carbon vancement of nanotechnology into an effective
nanotubes can induce asbestos-like inflammation new area in clinical medical practice.
and granulomas in female mice.29 It is possible Supported by grants from the University of Toronto Depart-
ment of Surgery Surgeon Scientist Program and Clinical Investi-
that the heavy-metal composition and physical gator Program, the Neurosurgery Research and Education Foun-
properties of nanomaterials, as well as their abil- dationAmerican Association of Neurological Surgeons (to Dr.
ity to enter vital organs, lead to unique toxic re- Kim), the Natural Sciences and Engineering Research Council of
Canada (to Dr. Kim and RGPIN288231-09 and NETGP35015-07 to
sponses. To date, there is no conclusive evidence Dr. Chan), the Canadian Institute of Health Research (MOP-74610,
of a known human toxic response that is specifi- to Dr. Rutka; and RMF-72551 and MOP-93532 to Dr. Chan), the
cally caused by nanomaterials. However, a study Canadian Cancer Society Research Institute (to Dr. Rutka), and
the Canadian Foundation for Innovation and the Ontario Inno-
showed that high doses of nanoparticle-based vation Trust (to Dr. Chan).
therapeutic agents (27 mg of small inhibitory RNA Dr. Chan reports receiving grant support from Parvus Thera-
[siRNA] vs. 9 mg per kilogram in 40-nm nanopar- peutics on behalf of the University of Toronto, cofounding Cyto-
diagnostics and the Fio Corporation and holding equity in both
ticles) led to reversible kidney toxicity.30 Magnet- companies, and having received fees for serving on the Scien-
ic nanoparticles used for thermal ablation have tific Advisory Board of Sigma-Aldrich Biotechnology in 2008
been shown to be retained in the urinary tract (in 2009. No other potential conflict of interest relevant to this ar-
ticle was reported.
patients with a history of urethral stricture) and Disclosure forms provided by the authors are available with
to result in treatment-related illness.31 In con- the full text of this article at NEJM.org.
We thank Drs. Wen Jiang, JeongJin A. Lee, and Jesse their critical reading, technical discussions, and editorial as-
lostranec for assistance with earlier versions of the manu-
K sistance; and AXS Biomedical Animation Studio in Toronto for
script; Drs. Andrew Tsourkas, Christopher Yip, Benjamin All- their assistance and for the figure in the Supplementary Ap-
man, Andres Lozano, Carter Snead, and Young-June Kim for pendix.
References
1. Terminology for nanomaterials. Pub- trial of CYT-6091: a pegylated colloidal 28. Derfus AM, Chan WCW, Bhatia SN.
licly available specification 136. London: gold-TNF nanomedicine. J Clin Oncol Probing the cytotoxicity of semiconductor
British Standards Institute, 2007. (http:// 2007;25:Suppl:163s. abstract. quantum dots. Nano Lett 2004;4:11-8.
www.nanointeract.net/x/file/PAS%20136 15. Visaria RK, Griffin RJ, Williams BW, 29. Poland CA, Duffin R, Kinloch I, et al.
.pdf.) et al. Enhancement of tumor thermal Carbon nanotubes introduced into the ab-
2. Xia Y, Xiong YJ, Lim B, Skrabalak SE. therapy using gold nanoparticle-assisted dominal cavity of mice show asbestos-like
Shape-controlled synthesis of metal nano- tumor necrosis factor-alpha delivery. Mol pathogenicity in a pilot study. Nat Nano-
crystals: simple chemistry meets complex Cancer Ther 2006;5:1014-20. technol 2008;3:423-8.
physics? Angew Chem Int Ed Engl 2009; 16. Kim TY, Kim DW, Chung JY, et al. 30. Hediel JD, Yu Z, Liu JYC, et al. Admin-
48:60-103. Phase I and pharmacokinetic study of istration in non-human primates of esca-
3. Peer D, Karp JM, Hong S, Farokhzad Genexol-PM, a cremophor-free, polymeric lating intravenous doses of targeted
OC, Margalit R, Langer R. Nanocarriers micelle-formulated paclitaxel, in patients nanoparticles containing ribonucleotide
as an emerging platform for cancer thera- with advanced malignancies. Clin Cancer reductase sub-unit M2 siRNA. Proc Natl
py. Nat Nanotechnol 2007;2:751-60. Res 2004;10:3708-16. Acad Sci U S A 2007;104:5715-21.
4. Council of the Canadian Academies. 17. Harisinghani MG, Barentsz J, Hahn 31. Johannsen M, Gneveckow U, Tay-
Small is different: a science perspective on PF, et al. Noninvasive detection of clini- moorian K, et al. Morbidity and quality of
the regulatory challenges of the nanoscale. cally occult lymph-node metastases in life during thermotherapy using magnetic
July 2008. (http://www.nanolawreport.com/ prostate cancer. N Engl J Med 2003;348: nanoparticles in locally recurrent prostate
JulyCanadaReport.pdf.) 2491-9. cancer: results of a prospective phase I
5. Thorek DLJ, Chen A, Czupryna J, 18. Enochs WS, Harsh G, Hochberg F, trial. Int J Hyperthermia 2007;23:315-23.
Tsourkas A. Superparamagnetic iron ox- Weissleder R. Improved delineation of 32. Schipper ML, Nakayama-Ratchford N,
ide nanoparticle probes for molecular im- human brain tumors on MR images us- Davis CR, et al. A pilot toxicology study of
aging. Ann Biomed Eng 2006;34:23-38. ing a long-circulating, superparamag- single-walled carbon nanotubes in a small
6. Resch-Genger U, Grabolle M, Cava- netic iron oxide agent. J Magn Reson sample of mice. Nat Nanotechnol 2008;3:
liere-Jaricot S, Nitschke R, Nann T. Quan- Imaging 1999;9:228-32. 216-21.
tum dots versus organic dyes as fluores- 19. Perrault SD, Walkey C, Jennings T, 33. Hauck TS, Anderson RE, Newbigging
cent labels. Nat Methods 2008;5:763-75. Fischer HC, Chan WC. Mediating tumor S, Chan WCW. In vivo quantum dot toxic-
7. McCarthy TD, Karellas P, Henderson targeting efficiency of nanoparticles ity assessment. Small 2010;6:138-44.
SA, et al. Dendrimers as drugs: discovery through design. Nano Lett 2009;9:1909-15. 34. Lidke DS, Nagy P, Heintzmann R, et
and preclinical and clinical development 20. Posthuma-Trumpie GA, Korf J, van al. Quantum dot ligands provide new in-
of dendrimer-based microbicides for HIV Amerongen AV. Lateral flow (immuno)as- sights into erbB/HER receptor-mediated
and STI prevention. Mol Pharm 2005;2: say: its strengths, weaknesses, opportuni- signal transduction. Nat Biotechnol 2004;
312-8. ties and threats: a literature survey. Anal 22:198-203.
8. Davis ME, Zuckerman JE, Choi CHJ, et Bioanal Chem 2009;393:569-82. 35. Chattopadhyay PK, Price DA, Harper
al. Evidence of RNAi in humans from sys- 21. Nam JM, Thaxton CS, Mirkin CA. TF, et al. Quantum dot semiconductor
temically administered siRNA via targeted Nanoparticle-based bio-bar codes for the nanocrystals for immunophenotyping by
nanoparticles. Nature 2010;464:1067-70. ultrasensitive detection of proteins. Sci- polychromatic flow cytometry. Nat Med
9. Sperling RA, Gil PR, Zhang F, Zanella ence 2003;301:1884-6. 2006;12:972-7.
M, Parak WJ. Biological applications of 22. Lefferts JA, Jannetto P, Tsongalis GJ. 36. Kim S, Lim YT, Soltesz EG, et al. Near-
gold nanoparticles. Chem Soc Rev 2008; Evaluation of the Nanosphere Verigene Sys- infrared fluorescent type II quantum dots
37:1896-908. tem and the Verigene F5/F2/MTHFR Nucleic for sentinel lymph node mapping. Nat
10. Liu ZA, Li XL, Tabakman SM, Jiang Acid Tests. Exp Mol Pathol 2009;87:105-8. Biotechnol 2004;22:93-7.
KL, Fan SS, Dai HJ. Multiplexed multicol- 23. Thaxton CS, Elghanian R, Thomas 37. Gao X, Cui Y, Levenson R, Chung L,
or Raman imaging of live cells with isoto- AD, et al. Nanoparticle-based bio-barcode Nie S. In vivo cancer targeting and imag-
pically modified single walled carbon assay redefines undetectable PSA and ing with semiconductor quantum dots.
nanotubes. J Am Chem Soc 2008;130: biochemical recurrence after radical pros- Nat Biotechnol 2004;22:969-76.
13540-1. tatectomy. Proc Natl Acad Sci U S A 2009; 38. Suh WH, Suh Y-H, Stucky GD. Multi-
11. Hobbs SK, Monsky WL, Yuan F, et al. 106:18437-42. functional nanosystems at the interface
Regulation of transport pathways in tu- 24. Hirsch LR, Stafford RJ, Bankson JA, of physical and life sciences. Nano Today
mor vessels: role of tumor type and mi- et al. Nanoshell-mediated near-infrared 2009;4:27-36.
croenvironment. Proc Natl Acad Sci U S A thermal therapy of tumors under mag- 39. Park JH, Gu L, von Maltzahn G,
1998;95:4607-12. netic resonance guidance. Proc Natl Acad Ruoslahti E, Bhatia SN, Sailor MJ. Biode-
12. Prencipe G, Tabakman SM, Welsher Sci U S A 2003;100:13549-54. gradable luminescent porous silicon nano
K, et al. PEG branched polymer for func- 25. Huang X, Neretina S, El-Sayed MA. particles for in vivo applications. Nat Ma-
tionalization of nanomaterials with ul- Gold nanorods: from synthesis and prop- ter 2009;8:331-6.
tralong blood circulation. J Am Chem Soc erties to biological and biomedical appli- 40. Gharbi N, Pressac M, Hadchouel M,
2009;131:4783-7. cations. Adv Mater 2009;21:4880-910. Szwarc H, Wilson SR, Moussa F. [60]fuller-
13. Alexis F, Pridgen E, Molnar LK, 26. Helms B, Meijer EW. Dendrimers at ene is a powerful antioxidant in vivo with
Farokhzad OC. Factors affecting the clear- work. Science 2006;313:929-30. no acute or subacute toxicity. Nano Lett
ance and biodistribution of polymeric 27. Nel AE, Madler L, Velegol D, et al. Un- 2005;5:2578-85.
nanoparticles. Mol Pharm 2008;5:505-15. derstanding biophysicochemical interac- Copyright 2010 Massachusetts Medical Society.
14. Libutti SK, Paciotti GF, Myer L, et al. tions at the nano-bio interface. Nat Mater
Preliminary results of a phase I clinical 2009;8:543-57.